Back to top
more

Bristol Myers Squibb (BMY)

(Real Time Quote from BATS)

$42.07 USD

42.07
4,553,145

-0.60 (-1.41%)

Updated Jul 23, 2024 12:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Bristol Myers Squibb (BMY) closed at $70.69, marking a +0.68% move from the previous day.

Exelixis (EXEL) Surges 25.4% so Far in 2023: Here's Why

by Zacks Equity Research

Exelixis' (EXEL) efforts to expand Cabometyx's label and develop additional drugs to expand its portfolio should reap rewards for the company.

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Will Bristol Myers (BMY) Gain From New Drugs' Label Expansion?

by Zacks Equity Research

Label expansion of Bristol Myers' (BMY) new drugs should help it somewhat combat the decline in Revlimid sales due to generic competition.

Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Bristol Myers Squibb (BMY) closed at $69.69, marking a +0.55% move from the previous day.

Bristol Myers' (BMY) Breyanzi Gets Positive CHMP Opinion

by Zacks Equity Research

Bristol Myers (BMY) receives a positive CHMP opinion for CAR T cell therapy with Breyanzi for relapsed or refractory large B-cell lymphoma after one prior treatment.

How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Bristol Myers Squibb (BMY) closed at $68.20, marking a +0.19% move from the previous day.

Bristol Myers (BMY) Gets Approval of Psoriasis Drug in EU

by Zacks Equity Research

Bristol Myers' (BMY) Sotyktu gets approval from the European Commission to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

Iovance (IOVA) Completes Rolling BLA Filing for Melanoma Drug

by Zacks Equity Research

Following the completion of Iovance's (IOVA) regulatory filing for its lead candidate in melanoma indication, the FDA has 60 days to determine the acceptability of the BLA for review.

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Incyte (INCY) Gets CRL for Jakafi Extended-Release Tablets

by Zacks Equity Research

The FDA issues a complete response letter to Incyte's (INCY) extended-release tablet formulation of Jakafi drug for the treatment of myelofibrosis, polycythemia vera and graft-versus-host disease.

Bristol Myers Squibb (BMY) Stock Moves -0.4%: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed at $67.24 in the latest trading session, marking a -0.4% move from the prior day.

3 Top Dividend Stocks to Maximize Your Retirement Income

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Bristol Myers Squibb (BMY) closed at $67.10, marking a -0.56% move from the previous day.

3 Top Dividend Stocks to Maximize Your Retirement Income

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Shaun Pruitt headshot

Should Investors Buy Bristol Myers or CVS Stock Near 52-week Lows?

by Shaun Pruitt

Investors are often on the lookout for strong companies that may be undervalued and present lucrative long-term opportunities.

Bristol Myers Squibb (BMY) Stock Moves -1.19%: What You Should Know

by Zacks Equity Research

In the latest trading session, Bristol Myers Squibb (BMY) closed at $65.72, marking a -1.19% move from the previous day.

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Exelixis' (EXEL) Cabozantinib Combo Study Fails to Meet Goal

by Zacks Equity Research

Exelixis' (EXEL) combo-drug study for kidney cancer fails to meet the primary endpoint of progression-free survival (PFS).

Bristol Myers (BMY) Gets EU Nod for Anemia Drug Reblozyl

by Zacks Equity Research

Bristol Myers Squibb (BMY) gets full marketing authorization from the European Commission, for Reblozyl for anemia associated with non-transfusion-dependent beta thalassemia treatment drug in adult patients.

Mirati's (MRTX) Q4 Loss Narrows, Krazati Records First Sales

by Zacks Equity Research

Mirati Therapeutics (MRTX) reports a narrower-than-expected Q4 loss and records first sales of Krazati. Stock rises in after-hours trading.